Use of the syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers

Viruses

Volumn 4, Issue 12, 2012, Pages 3754-3784

  Wahl Jensen, Victoria ^a   Bollinger, Laura ^a   Safronetz, David ^b   De Kok Mercado, Fabian ^b   Scott, Dana P ^b   Ebihara, Hideki ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Ebola; Filovirus; Hamster model; Pathogenesis; Rodent model

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EBOLA VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOLOGICAL REAGENT; REAGENT; UNCLASSIFIED DRUG;

BLOOD CLOTTING; CLINICAL FEATURE; CLINICAL RESEARCH; COMPARATIVE STUDY; DISEASE MODEL; EBOLA HEMORRHAGIC FEVER; EXPERIMENTAL ANIMAL; GUINEA PIG; HEMATOLOGICAL PARAMETERS; IN VIVO STUDY; KIDNEY; LIVER; LUNG; LYMPH NODE; MOUSE; NONHUMAN; PATHOGENESIS; PATHOLOGY; PRIMATE; REVIEW; SPLEEN; STRAIN DIFFERENCE; SYRIAN HAMSTER; VASCULAR DISEASE; VIRUS HEMORRHAGIC FEVER;

ANIMALS; CRICETINAE; DISEASE MODELS, ANIMAL; EBOLAVIRUS; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MESOCRICETUS; MICE; PRIMATES;

ANIMALIA; CAVIA; CRICETINAE; EBOLA VIRUS; MARBURGVIRUS; MESOCRICETUS AURATUS; MUS; PRIMATES; RODENTIA;

EID: 84871856367     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4123754     Document Type: Review

References (109)

1. Schnittler, H.J.; Feldmann, H., Viral hemorrhagic fever--a vascular disease? Thromb. Haemostasis 2003, 89, 967-972.
2. Zaki, S.R.; Goldsmith, C.S. Pathologic features of filovirus infections in humans. Curr. Top. Microbiol. Immunol. 1999, 235, 97-116.
3. Bwaka, M.A.; Bonnet, M.J.; Calain, P.; Colebunders, R.; De Roo, A.; Guimard, Y.; Katwiki, K.R.; Kibadi, K.; Kipasa, M.A.; Kuvula, K.J.; et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J. Infect. Dis. 1999, 179, S1-S7.
4. Formenty, P.; Hatz, C.; Le Guenno, B.; Stoll, A.; Rogenmoser, P.; Widmer, A. Human infection due to Ebola virus, subtype Cote d'Ivoire: Clinical and biologic presentation. J. Infect. Dis. 1999, 179, S48-S53.
5. Kuhn, J.H. Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. Arch. Virol. Suppl. 2008, 20, 13-360.
6. Smith, D.H.; Francis, D.P.; Simpson, D.I. African Haemorrhagic Fever in the Southern Sudan, 1976: The Clinical Manifestations. In Ebola Virus Haemorrhagic Fever-Proceedings of an International Colloquium on Ebola Virus Infection and Other Haemorrhagic Fevers, Antwerp, Belgium, December 6-8, 1977.; Pattyn, S.R., Ed.; Elsevier North Holland Biomedical Press: Amsterdam, Netherlands, 1978; pp 28-31. Available online: http://www.itg.be/internet/ebola/default.htm (accessed on 14 June 2012).
7. Sureau, P.H. Firsthand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire. Rev. Infect. Dis. 1989, 11, S790-S793.
8. World Health Organization. Ebola haemorrhagic fever in Sudan, 1976. Bull. World Health Organ. 1978, 52, 247-50. Available online: http://whqlibdoc.who.int/bulletin/1978/Vol56-No2/bulletin_1978_56%282%29_247-270.pdf (accessed on 19 June 2012).
9. Rollin, P.E.; Bausch, D.G.; Sanchez, A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J. Infect. Dis. 2007, 196, S364-S371.
10. Richards, G.A.; Murphy, S.; Jobson, R.; Mer, M.; Zinman, C.; Taylor, R.; Swanepoel, R.; Duse, A.; Sharp, G.; De La Rey, I.C.; et al. Unexpected Ebola virus in a tertiary setting: clinical and epidemiologic aspects. Crit. Care Med. 2000, 28, 240-244.
11. Dietrich, M.; Schumacher, H.H.; Peters, D.; Knobloch, J. Human pathology of Ebola (MARIDI) virus Infection in the Sudan. In Ebola Virus Haemorrhagic Fever-Proceedings of an International Colloquium on Ebola Virus Infection and Other Haemorrhagic Fevers, Antwerp, Belgium, December 6-8, 1977; Pattyn, S.R., Ed.; Elsevier North Holland Biomedical Press: Amsterdam, Netherlands, 1978; pp 37-41. Available online: http://www.itg.be/internet/ebola/default.htm (accessed on 14 June 2012).
12. Sanchez, A.; Lukwiya, M.; Bausch, D.; Mahanty, S.; Sanchez, A.J.; Wagoner, K.D.; Rollin, P.E. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: Cellular responses, virus load, and nitric oxide levels. J. Virol. 2004, 78, 10370-10377.
13. Kortepeter, M.G.; Bausch, D.G.; Bray, M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J. Infect. Dis. 2011, 204, S810-S816.
14. Murphy, F.A. Pathology of Ebola virus infection. In Ebola Virus Haemorrhagic Fever-Proceedings of an International Colloquium on Ebola Virus Infection and Other Haemorrhagic Fevers, Antwerp, Belgium, December 6-8, 1977; Pattyn, S.R., Ed.; Elsevier North Holland Biomedical Press: Amsterdam, Netherlands, 1978; pp 41-53. Available online: http://www.itg.be/internet/ebola/default.htm (accessed on 14 June 2012).
15. Baize, S.; Leroy, E.M.; Georges, A.J.; Georges-Courbot, M.C.; Capron, M.; Bedjabaga, I.; Lansoud-Soukate, J.; Mavoungou, E. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 2002, 128, 163-168.
16. Wauquier, N.; Becquart, P.; Padilla, C.; Baize, S.; Leroy, E.M. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Neglected Tropical Diseases 2010, 4, e837.
17. Villinger, F.; Rollin, P.E.; Brar, S.S.; Chikkala, N.F.; Winter, J.; Sundstrom, J.B.; Zaki, S.R.; Swanepoel, R.; Ansari, A.A.; Peters, C.J. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J. Infect. Dis. 1999, 179, S188-S191.
18. Hutchinson, K.L.; Rollin, P.E. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J. Infect. Dis. 2007, 196, S357-S363.
19. Food and Drug Administration. New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs when Human Efficacy Studies are not Ethical or Feasible. Federal Register 2002, 67, 37988-37998.
20. Bray, M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 2001, 82, 1365-1373.
21. Connolly, B.M.; Steele, K.E.; Davis, K.J.; Geisbert, T.W.; Kell, W.M.; Jaax, N.K.; Jahrling, P.B. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 1999, 179, S203-S217.
22. Bray, M.; Davis, K.; Geisbert, T.; Schmaljohn, C.; Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 1998, 178, 651-661.
23. Cilloniz, C.; Ebihara, H.; Ni, C.; Neumann, G.; Korth, M.J.; Kelly, S.M.; Kawaoka, Y.; Feldmann, H.; Katze, M.G. Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection. J. Virol. 2011, 85, 9060-9068.
24. Geisbert, T.W.; Pushko, P.; Anderson, K.; Smith, J.; Davis, K.J.; Jahrling, P.B. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 2002, 8, 503-507.
25. Reed, D.S.; Mohamadzadeh, M. Status and challenges of filovirus vaccines. Vaccine 2007, 25, 1923-1934.
26. Ebihara, H.; Rockx, B.; Marzi, A.; Feldmann, F.; Haddock, E.; Brining, D.; LaCasse, R.A.; Gardner, D.; Feldmann, H. Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J. Infect. Dis. 2011, 204, S991-S999.
27. Ebihara, H.; Zivcec, M.; Gardner, D.; Falzarano, D.; Lacasse, R.; Rosenke, R.; Long, D.; Haddock, E.; Fischer, E.; Kawaoka, Y.; et al. A Syrian golden hamster model recapitulating Ebola hemorrhagic fever. J. Infect. Dis. 2012, doi:10.1093/infdis/jis626.
28. Michelow, I.C.; Lear, C.; Scully, C.; Prugar, L.I.; Longley, C.B.; Yantosca, L.M.; Ji, X.; Karpel, M.; Brudner, M.; Takahashi, K.; et al. High-dose mannose-binding lectin therapy for Ebola virus infection. J. Infect. Dis. 2011, 203, 175-179.
29. Bukreyev, A.; Marzi, A.; Feldmann, F.; Zhang, L.; Yang, L.; Ward, J.M.; Dorward, D.W.; Pickles, R.J.; Murphy, B.R.; Feldmann, H.; et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009, 383, 348-361.
30. Bukreyev, A.; Rollin, P.E.; Tate, M.K.; Yang, L.; Zaki, S.R.; Shieh, W.J.; Murphy, B.R.; Collins, P.L.; Sanchez, A. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol. 2007, 81, 6379-6388.
31. Bukreyev, A.; Yang, L.; Zaki, S.R.; Shieh, W.J.; Rollin, P.E.; Murphy, B.R.; Collins, P.L.; Sanchez, A. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol. 2006, 80, 2267-2279.
32. Marzi, A.; Ebihara, H.; Callison, J.; Groseth, A.; Williams, K.J.; Geisbert, T.W.; Feldmann, H. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J. Infect. Dis. 2011, 204, S1066-S10674.
33. Garbutt, M.; Liebscher, R.; Wahl-Jensen, V.; Jones, S.; Moller, P.; Wagner, R.; Volchkov, V.; Klenk, H.D.; Feldmann, H.; Stroher, U. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 2004, 78, 5458-5465.
34. Geisbert, T.W.; Daddario-Dicaprio, K.M.; Lewis, M.G.; Geisbert, J.B.; Grolla, A.; Leung, A.; Paragas, J.; Matthias, L.; Smith, M.A.; Jones, S.M.; et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathogens 2008, 4, e1000225.
35. Jones, S.M.; Stroher, U.; Fernando, L.; Qiu, X.; Alimonti, J.; Melito, P.; Bray, M.; Klenk, H.D.; Feldmann, H. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J. Infect. Dis. 2007, 196, S404-S412.
36. Qiu, X.; Fernando, L.; Alimonti, J.B.; Melito, P.L.; Feldmann, F.; Dick, D.; Stroher, U.; Feldmann, H.; Jones, S.M. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PloS One 2009, 4, e5547.
37. Geisbert, T.W.; Daddario-Dicaprio, K.M.; Geisbert, J.B.; Reed, D.S.; Feldmann, F.; Grolla, A.; Stroher, U.; Fritz, E.A.; Hensley, L.E.; Jones, S.M.; et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008, 26, 6894-6900.
38. Jones, S.M.; Feldmann, H.; Stroher, U.; Geisbert, J.B.; Fernando, L.; Grolla, A.; Klenk, H.D.; Sullivan, N.J.; Volchkov, V.E.; Fritz, E.A.; et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 2005, 11, 786-790.
39. Gilligan, K.; Geisbert, J.; Jahrling, P.; Anderson, K. Assessment of Protective Immunity Conferred by Recombinant Vaccinia Viruses to Guinea Pigs Challenged with Ebola Virus. In Vaccines 97: Molecular Approaches to the Control of Infectious Diseases; Brown, F., Burton, D., Doherty, P., Mekalanos, J., Norrby, E., Eds.; Cold Spring Harbor Laboratory Press: Plainview, NY, USA, 1997; pp 87-92.
40. Wilson, J.A.; Hart, M.K. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J. Virol. 2001, 75, 2660-2664.
41. Pushko, P.; Bray, M.; Ludwig, G.V.; Parker, M.; Schmaljohn, A.; Sanchez, A.; Jahrling, P.B.; Smith, J.F. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000, 19, 142-153.
42. Olinger, G.G.; Bailey, M.A.; Dye, J.M.; Bakken, R.; Kuehne, A.; Kondig, J.; Wilson, J.; Hogan, R.J.; Hart, M.K. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J. Virol. 2005, 79, 14189-14196.
43. Phoolcharoen, W.; Dye, J.M.; Kilbourne, J.; Piensook, K.; Pratt, W.D.; Arntzen, C.J.; Chen, Q.; Mason, H.S.; Herbst-Kralovetz, M.M. A Nonreplicating Subunit Vaccine Protects Mice Against Lethal Ebola Virus Challenge. In Proceedings of the National Academy of Sciences of the United States of America 2011, 108, 20695-20700.
44. Pushko, P.; Geisbert, J.; Parker, M.; Jahrling, P.; Smith, J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 2001, 75, 11677-11685.
45. Wilson, J.A.; Bray, M.; Bakken, R.; Hart, M.K. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 2001, 286, 384-390.
46. Gupta, M.; Mahanty, S.; Bray, M.; Ahmed, R.; Rollin, P.E. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol. 2001, 75, 4649-4654.
47. Gupta, M.; Mahanty, S.; Greer, P.; Towner, J.S.; Shieh, W.J.; Zaki, S.R.; Ahmed, R.; Rollin, P.E. Persistent infection with ebola virus under conditions of partial immunity. J. Virol. 2004, 78, 958-967.
48. Warfield, K.L.; Bosio, C.M.; Welcher, B.C.; Deal, E.M.; Mohamadzadeh, M.; Schmaljohn, A.; Aman, M.J.; Bavari, S. Ebola virus-like particles protect from lethal Ebola virus infection. In Proceedings of the National Academy of Sciences of the United States of America 2003, 100, 15889-15894.
49. Rao, M.; Bray, M.; Alving, C.R.; Jahrling, P.; Matyas, G.R. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J. Virol. 2002, 76, 9176-9185.
50. Warfield, K.L.; Swenson, D.L.; Olinger, G.G.; Kalina, W.V.; Viard, M.; Aitichou, M.; Chi, X.; Ibrahim, S.; Blumenthal, R.; Raviv, Y.; et al. Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J. Infect. Dis. 2007, 196, S276-S283.
51. Feldmann, H.; Jones, S.M.; Daddario-DiCaprio, K.M.; Geisbert, J.B.; Stroher, U.; Grolla, A.; Bray, M.; Fritz, E.A.; Fernando, L.; Feldmann, F.; et al. Effective post-exposure treatment of Ebola infection. PLoS Pathogens 2007, 3, e2.
52. Jahrling, P.B.; Geisbert, J.B.; Swearengen, J.R.; Larsen, T.; Geisbert, T.W. Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 2007, 196, S400-S403.
53. Jahrling, P.B.; Geisbert, J.; Swearengen, J.R.; Jaax, G.P.; Lewis, T.; Huggins, J.W.; Schmidt, J.J.; LeDuc, J.W.; Peters, C.J. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. Suppl. 1996, 11, 135-140.
54. Jahrling, P.B.; Geisbert, T.W.; Geisbert, J.B.; Swearengen, J.R.; Bray, M.; Jaax, N.K.; Huggins, J.W.; LeDuc, J.W.; Peters, C.J. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 1999, 179, S224-S234.
55. Parren, P.W.; Geisbert, T.W.; Maruyama, T.; Jahrling, P.B.; Burton, D.R., Pre-and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 2002, 76, 6408-6412.
56. Oswald, W.B.; Geisbert, T.W.; Davis, K.J.; Geisbert, J.B.; Sullivan, N.J.; Jahrling, P.B.; Parren, P.W.; Burton, D.R. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathogens 2007, 3, e9.
57. Enterlein, S.; Warfield, K.L.; Swenson, D.L.; Stein, D.A.; Smith, J.L.; Gamble, C.S.; Kroeker, A.D.; Iversen, P.L.; Bavari, S.; Muhlberger, E. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 2006, 50, 984-993.
58. Warfield, K.L.; Swenson, D.L.; Olinger, G.G.; Nichols, D.K.; Pratt, W.D.; Blouch, R.; Stein, D.A.; Aman, M.J.; Iversen, P.L.; Bavari, S. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathogens 2006, 2, e1.
59. Warren, T.K.; Warfield, K.L.; Wells, J.; Swenson, D.L.; Donner, K.S.; Van Tongeren, S.A.; Garza, N.L.; Dong, L.; Mourich, D.V.; Crumley, S.; et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med. 2010, 16, 991-994.
60. Swenson, D.L.; Warfield, K.L.; Warren, T.K.; Lovejoy, C.; Hassinger, J.N.; Ruthel, G.; Blouch, R.E.; Moulton, H.M.; Weller, D.D.; Iversen, P.L.; Bavari, S. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob. Agents Chemothe. r 2009, 53, 2089-2099.
61. Adler, S. Origin of the golden hamster Cricetus auratus as a laboratory animal. Nature 1948, 162, 256.
62. Boschert, K. Hamsters: Biology, care, diseases & models. Available online: http://netvet.wustl.edu/species/hamsters/hamstbio.txt (accessed on 26 June 2012).
63. Murphy, M.R. History of the Capture and Domestication of the Syrian Golden Hamster (Mesocricetus auratus Waterhouse). In The Hamster: Reproduction and Behavior; Siegel, H.I., Ed.; Plenum Press: New York, NY, USA, 1985; pp 3-20.
64. Smith, G.D. Taxonomy and History. In The Laboratory Rabbit, guinea pig, hamster, and other rodents., Suckow, M.A.; Stevens, K.A.; Wilson, R.P., Eds. Acedemic Press: Waltham MA, 2012.
65. Simonsen Laboratories. Origin and Strain Designation: Syrian Hamsters. Available online: http://www.simlab.com/products.html (accessed on 20 March 2012).
66. Charles River Laboratories International. Charles River History. Available online: http://www.criver.com/en-us/aboutus/history/Pages/home.aspx (accessed on 20 March 2012).
67. Charles River Laboratories International. LVG golden syrian hamsters 2012 US pricing. Available online: http://www.criver.com/sitecollectiondocuments/rm_rm_c_lvg_ golden_syrian_hamsters.pdf (accessed on 20 March 2012).
68. Harlan Laboratories. Syrian Hamster. 3248 Harlan Research Models and Services (RMS) Datasheets v4. Avaiable online: http://www.harlan.com/products_and_services/ research_models_and_services/research_models (accessed on 20 March 2012).
69. Kunstyr, I.; Schoeneberg, U.; Friedhoff, K.T. Host specificity of Giardia muris isolates from mouse and golden hamster. Parasitol. Res. 1992, 78, 621-622.
70. Bio Breeders. Hamster models and applications for human diseases. Available online: http://www.biobreeders.com/hamstermodels.html (accessed on 26 June 2012).
71. U.S. Department of Agriculture. Animals Used in Research: Animal Care Annual Report of Activities, Fiscal Year 2010. Available online: http://www.aphis.usda.gov/ animal_welfare/efoia/downloads/2010_Animals_Used_In_Research.pdf (accessed 30 June 2012)
72. Hankenson, F.C.; Van Hoosier, G.L. Biology and Diseases of Hamsters. In Laboratory Animal Medicine; Fox, J.G., Anderson, L.C., Loew, F.L., Quimby, F.W., Eds. Academic Press: San Diego, CA, USA, 2002; pp 167-202.
73. Zlotnik, I. "Marburg disease". The Pathology of Experimentally Infected Hamsters. In Marburg Virus Disease; Martini, G.A., Siegert, R., Eds.; Springer-Verlag: Berlin, Germany, 1971; pp. 129-135.
74. Hammerbeck, C.D.; Hooper, J.W. T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome. J. Virol. 2011, 85, 9929-9944.
75. Wahl-Jensen, V.; Chapman, J.; Asher, L.; Fisher, R.; Zimmerman, M.; Larsen, T.; Hooper, J.W. Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters. J. Virol. 2007, 81, 7449-7462.
76. Safronetz, D.; Zivcec, M.; Lacasse, R.; Feldmann, F.; Rosenke, R.; Long, D.; Haddock, E.; Brining, D.; Gardner, D.; Feldmann, H.; et al. Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus. PLoS Pathogens 2011, 7, e1002426.
77. Campen, M.J.; Milazzo, M.L.; Fulhorst, C.F.; Obot Akata, C.J.; Koster, F. Characterization of shock in a hamster model of hantavirus infection. Virology 2006, 356, 45-49.
78. Milazzo, M.L.; Eyzaguirre, E.J.; Molina, C.P.; Fulhorst, C.F. Maporal viral infection in the Syrian golden hamster: A model of hantavirus pulmonary syndrome. J. Infect. Dis. 2002, 186, 1390-1395.
79. Hooper, J.W.; Larsen, T.; Custer, D.M.; Schmaljohn, C.S. A lethal disease model for hantavirus pulmonary syndrome. Virology 2001, 289, 6-14.
80. Gowen, B.B.; Julander, J.G.; London, N.R.; Wong, M.H.; Larson, D.; Morrey, J.D.; Li, D.Y.; Bray, M. Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol. J. 2010, 7, 240.
81. Sbrana, E.; Xiao, S.Y.; Popov, V.L.; Newman, P.C.; Tesh, R.B. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values. Am. J. Trop. Med. Hyg. 2006, 74, 1084-1089.
82. Xiao, S.Y.; Zhang, H.; Guzman, H.; Tesh, R.B. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J. Infect. Dis. 2001, 183, 1437-1444.
83. Fisher, A.F.; Tesh, R.B.; Tonry, J.; Guzman, H.; Liu, D.; Xiao, S.Y. Induction of severe disease in hamsters by two sandfly fever group viruses, Punta toro and Gabek Forest (Phlebovirus, Bunyaviridae), similar to that caused by Rift Valley fever virus. Am. J. Trop. Med. Hyg. 2003, 69, 269-276.
84. Vela, E.M.; Knostman, K.A.; Mott, J.M.; Warren, R.L.; Garver, J.N.; Vela, L.J.; Stammen, R.L. Genistein, a general kinase inhibitor, as a potential antiviral for arenaviral hemorrhagic fever as described in the Pirital virus-Syrian golden hamster model. Antivir. Res. 2010, 87, 318-328.
85. Li, G.; Duan, T.; Wu, X.; Tesh, R.B.; Soong, L.; Xiao, S.Y. Yellow fever virus infection in Syrian golden hamsters: Relationship between cytokine expression and pathologic changes. Int. J. Clin. Exp. Pathol. 2008, 1, 169-179.
86. Sbrana, E.; Mateo, R.I.; Xiao, S.Y.; Popov, V.L.; Newman, P.C.; Tesh, R.B. Clinical laboratory, virologic, and pathologic changes in hamsters experimentally infected with Pirital virus (Arenaviridae): A rodent model of Lassa fever. Am. J. Trop. Med. Hyg. 2006, 74, 1096-1102.
87. Xiao, S.Y.; Zhang, H.; Yang, Y.; Tesh, R.B. Pirital virus (Arenaviridae) infection in the syrian golden hamster, Mesocricetus auratus: a new animal model for arenaviral hemorrhagic fever. Am. J. Trop. Med. Hyg. 2001, 64, 111-118.
88. Lima, E.Q.; Nogueira, M.L. Viral hemorrhagic fever-induced acute kidney injury. Semin. Nephrol. 2008, 28, 409-415.
89. Geisbert, T.W.; Young, H.A.; Jahrling, P.B.; Davis, K.J.; Larsen, T.; Kagan, E.; Hensley, L.E. Pathogenesis of Ebola hemorrhagic fever in primate models: Evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am. J. Pathol. 2003, 163, 2371-2382.
90. Geisbert, T.W.; Young, H.A.; Jahrling, P.B.; Davis, K.J.; Kagan, E.; Hensley, L.E. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 2003, 188, 1618-1629.
91. Ryabchikova, E.I.; Kolesnikova, L.V.; Netesov, S.V. Animal pathology of filoviral infections. Curr. Top Microbiol. Immunol. 1999, 235, 145-173.
92. Feldmann, H.; Geisbert, T.W. Ebola haemorrhagic fever. Lancet 2011, 377, 849-862.
93. Aleksandrowicz, P.; Wolf, K.; Falzarano, D.; Feldmann, H.; Seebach, J.; Schnittler, H. Viral haemorrhagic fever and vascular alterations. Hamostaseologie 2008, 28, 77-84.
94. Zivcec, M.; Safronetz, D.; Haddock, E.; Feldmann, H.; Ebihara, H. Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J. Immunol. Meth. 2011, 368, 24-35.
95. McNees, A.L.; Vilchez, R.A.; Heard, T.C.; Sroller, V.; Wong, C.; Herron, A.J.; Hamilton, M.J.; Davis, W.C.; Butel, J.S. SV40 lymphomagenesis in Syrian golden hamsters. Virology 2009, 384, 114-124.
96. Dondji, B.; Sun, T.; Bungiro, R.D.; Vermeire, J.J.; Harrison, L.M.; Bifulco, C.; Cappello, M. CD4 T cells mediate mucosal and systemic immune responses to experimental hookworm infection. Parasite Immunol. 2010, 32, 406-413.
97. Dondji, B.; Bungiro, R.D.; Harrison, L.M.; Vermeire, J.J.; Bifulco, C.; McMahon-Pratt, D.; Cappello, M. Role for nitric oxide in hookworm-associated immune suppression. Infect. Immun. 2008, 76, 2560-2567.
98. Yang, K.; Zhang, G.; Mei, J.; Chen, D.; Wu, M. Screening and analysis of pathogenic genes during DMBA-induced buccal mucosa carcinogenesis in golden hamsters. Oncol. Rep. 2010, 23, 1619-1624.
99. Yu, T.; Wang, X.Y.; Gong, R.G.; Li, A.; Yang, S.; Cao, Y.T.; Wen, Y.M.; Wang, C.M.; Yi, X.Z. The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J. Exp. Clin. Canc. Res. 2009, 28, 64.
100. Hohlweg, U.; Hosel, M.; Dorn, A.; Webb, D.; Hilger-Eversheim, K.; Remus, R.; Schmitz, B.; Buettner, R.; Schramme, A.; Corzilius, L.; et al. Intraperitoneal dissemination of Ad12-induced undifferentiated neuroectodermal hamster tumors: De novo methylation and transcription patterns of integrated viral and of cellular genes. Virus Res. 2003, 98, 45-56.
101. Maywood, E.S.; Chahad-Ehlers, S.; Garabette, M.L.; Pritchard, C.; Underhill, P.; Greenfield, A.; Ebling, F.J.; Akhtar, R.A.; Kyriacou, C.P.; Hastings, M.H.; et al. Differential testicular gene expression in seasonal fertility. J. Biol. Rhythm. 2009, 24, 114-125.
102. Bradley, K.C.; Boulware, M.B.; Jiang, H.; Doerge, R.W.; Meisel, R.L.; Mermelstein, P.G. Changes in gene expression within the nucleus accumbens and striatum following sexual experience. Gene Brain Behav. 2005, 4, 31-44.
103. Matsui, M.; Rouleau, V.; Bruyere-Ostells, L.; Goarant, C. Gene expression profiles of immune mediators and histopathological findings in animal models of leptospirosis: comparison between susceptible hamsters and resistant mice. Infect Immun. 2011, 79, 4480-4492.
104. Gowen, B.B.; Fairman, J.; Dow, S.; Troyer, R.; Wong, M.H.; Jung, K.H.; Melby, P.C.; Morrey, J.D. Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antivir. Res. 2009, 81, 37-46.
105. Gowen, B.B.; Judge, J.W.; Wong, M.H.; Jung, K.H.; Aylsworth, C.F.; Melby, P.C.; Rosenberg, B.; Morrey, J.D. Immunoprophylaxis of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with recombinant Eimeria profilin-like antigen. Int. Immunopharm. 2008, 8, 1089-1094.
106. Mendez, S.; Valenzuela, J.G.; Wu, W.; Hotez, P.J. Host cytokine production, lymphoproliferation, and antibody responses during the course of Ancylostoma ceylanicum infection in the Golden Syrian hamster. Infect. Immun. 2005, 73, 3402-3407.
107. Rockx, B.; Brining, D.; Kramer, J.; Callison, J.; Ebihara, H.; Mansfield, K.; Feldmann, H. Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection. J. Virol. 2011, 85, 7658-7671.
108. Rama Iniguez, S.; Dea-Ayuela, M.A.; Sanchez-Brunete, J.A.; Torrado, J.J.; Alunda, J.M.; Bolas-Fernandez, F. Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation. Antimicrob. Agents Chemother. 2006, 50, 1195-1201.
109. Brown, K.S.; Safronetz, D.; Marzi, A.; Ebihara, H.; Feldmann, H. Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J. Virol. 2011, 85, 12781-12791.